Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
?
B****
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Satellos Bioscience Inc. | -1.460% | 21.622% | 72.194% | 18.421% | 67.079% | 230.073% | - |
| Larimar Therapeutics Inc. | -1.940% | 14.286% | -8.982% | -10.588% | -8.434% | -20.000% | -79.034% |
| Vaxart Inc. | 0.410% | -8.889% | 74.468% | -31.667% | 75.714% | -51.093% | -93.692% |
News
2 No-Brainer AI Stocks to Buy Hand Over Fist for 2026
Leading tech companies continue to report insatiable demand for artificial intelligence (AI). This is driving tremendous investment in chips, data centers, and cloud platforms. The AI market is
Nvidia's 85% GPU Market Share Faces Growing Competition: Is This AI Stock Still a Buy for 2026?
When you're talking about the biggest stock market stories of 2025, Nvidia (NASDAQ: NVDA) is a name that keeps coming up. The company has been one of the biggest winners of the artificial
MarketBeat Week in Review – 01/19 - 01/23
After moving sharply lower on tariff fears to start the week, stocks rallied as most economic indicators point to an economy that’s growing strongly. An in-line reading on the November PCE inflation
